ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1640727
Pharmacist-Led Remote Follow-up Service for Non-Metastatic Breast Cancer Patients: A Prospective Randomised Controlled Trial of Pharmaceutical Intervention
Provisionally accepted
- 1Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
- 2Department of Endocrinology, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Non-metastatic breast cancer accounts for 87.8% of breast cancer cases. However, the high risk of drug adverse drug reactions due to multiple combined medications, along with the urgent need for out-of-hospital medication adherence and management, poses substantial challenges. Traditional treatments often fail to meet the full-cycle management needs of patients. Remote pharmaceutical follow-up, as an emerging model, may address these issues. This study aimed to investigate the intervention effect of remote pharmaceutical services via a follow-up app on non-metastatic breast cancer patients. Methods: From May 2023 to March 2025, 178 patients with non-metastatic breast cancer were enrolled and randomly assigned to an intervention group (receiving remote pharmaceutical follow-up via an app) or a control group (receiving only routine treatment), with a 6-month follow-up period. The primary outcome was the incidence of severe adverse drug reactions, while secondary outcomes included medication adherence scores, pharmaceutical knowledge scores, and quality of life assessments. Results: The incidence of severe adverse drug reactions in the intervention group (20.2%) was significantly lower than that in the control group (50.0%, P<0.01), with notable improvements particularly in non-hematological adverse drug reactions. The intervention group also demonstrated significantly higher pharmaceutical knowledge scores and medication adherence scores compared to the control group (P<0.05). In terms of quality of life, the intervention group showed greater improvements in symptom scores and overall composite scores (P<0.01), with faster recovery of global health and functional scores in the late follow-up phase. Conclusion: Remote pharmaceutical services delivered via a follow-up app effectively reduce the incidence of severe adverse drug reactions and improve medication knowledge, adherence, and quality of life in non-metastatic breast cancer patients. This model provides a viable new approach for out-of-hospital management and highlights the value of pharmacists in the full-cycle management of oncology care. Future research should further explore preventive strategies for hematological adverse drug reactions and extend the follow-up period to refine the clinical application of this management model.
Keywords: Non-metastatic breast cancer, pharmacist, Follow-up service, adverse drug reactions, Quality of Life
Received: 04 Jun 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 WU, Huang, Liang, Wang, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yin Zhang, Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.